Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo, Kwang–Hyub Han, Sheng-Long Ye, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 245-260
Open Access | Times Cited: 239

Showing 1-25 of 239 citing articles:

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 480
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 294
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
QiJiong Li, Minke He, Huanwei Chen, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 2, pp. 150-160
Closed Access | Times Cited: 169
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 354-367
Open Access | Times Cited: 88
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 78
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
Chi‐Leung Chiang, K.W. Chiu, Kenneth Sik Kwan Chan, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 169-178
Closed Access | Times Cited: 72
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 64
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 41
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 16
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 9
Treatment and the prognosis of hepatocellular carcinoma in Asia
Takuji Torimura, Hideki Iwamoto
Liver International (2021) Vol. 42, Iss. 9, pp. 2042-2054
Open Access | Times Cited: 83
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 6, pp. 539-544
Open Access | Times Cited: 68
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 399-406
Open Access | Times Cited: 54
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302
Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba, et al.
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 440-450
Open Access | Times Cited: 51
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 593-604
Open Access | Times Cited: 32
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 32
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1423-1423
Open Access | Times Cited: 32
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1798-1798
Open Access | Times Cited: 26
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Darine Daher, Karim Seif El Dahan, Amit G. Singal
Journal of Liver Cancer (2023) Vol. 23, Iss. 1, pp. 127-142
Open Access | Times Cited: 22
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Ming-Da Wang, Yong‐Kang Diao, Lan‐Qing Yao, et al.
iLiver (2024) Vol. 3, Iss. 1, pp. 100083-100083
Open Access | Times Cited: 14
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Keiichi Akahoshi, Junichi Shindoh, Minoru Tanabe, et al.
Liver Cancer (2024), pp. 1-11
Open Access | Times Cited: 13
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
Jiahao Li, Yingnan Liu, Ruipeng Zheng, et al.
Life Sciences (2024) Vol. 342, pp. 122540-122540
Open Access | Times Cited: 9
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 756-770
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top